Yin, Xianli

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology

Gastric Cancer Management and OutcomesCancer Immunotherapy and Biomarkers

Cited by 690

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.

Liu, D., Gong, J., Liu, T., Li, K., Yin, X., Liu, Y., Wang, Y., Wang, L., Wang, W., Zhang, Y., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 16

Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

Li, J., Wang, Z., Huang, J., Ba, Y., Cao, B., Luo, S., Li, W., Bai, C., Song, Z., Xiong, J., et al. (2026) · The Lancet Gastroenterology & Hepatology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 3